

OPTIMA HEALTH COMMUNITY CARE

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: *The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-319-5003. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete forms will delay the process. All questions must be answered.*

Drug Requested: **HEPATITIS-C ANTIVIRALS** [MEDICAID](#)

Treatment is being prescribed by or in consultation with:

Gastroenterologist Hepatologist ID Specialist Transplant Specialist Other: _____

DRUG INFORMATION: Complete information below. If incomplete, authorization process will be delayed.

Drug Name/Form: _____ Strength: _____

Dosing Schedule/Quantity per Day: _____ Length of Therapy: _____

Diagnosis: _____ ICD CODE, if applicable: _____

CLINICAL CRITERIA: Check applicable boxes below in each section. If not met, authorization process will be delayed.

DIAGNOSIS

Chronic Hepatitis C Compensated cirrhosis Decompensated cirrhosis (Child-Pugh score class B or C)
 Hepatocellular carcinoma Status post-liver transplant

HCV Genotype: 1a (polymorphism Yes No N/A (If yes, submit test results) 1b 2 3 4 5 6

Choose One: Treatment initiation Continuation of therapy, current week:

ADHERANCE

Prescriber has assessed the member for adherence with medical and pharmacological treatment. Yes No

Prescribed has reviewed Hepatitis C Patient Treatment Agreement with the member. Signed agreement attached. Yes No

SUBSTANCE USE DISORDER SCREENING

The Prescriber has evaluated the member for current substance use disorder including alcohol use disorder.

- Members identified with a substance use disorder should be referred for treatment.
- **Member cannot be denied Hepatitis C treatment for sole reason of substance use.** Yes No
- Testing for illicit drug and/or alcohol use is **not** required.

OTHER CO-MORBID CONDITION(S)

Decompensated cirrhosis (Child-Pugh score greater than 6 [class B or C]) Yes No

Hx severe renal impairment (eGFR <30 mL/min/1.73m²) or end stage renal disease requiring hemodialysis Yes No

If yes to any, please give details: _____

LAB VALUES

| | | |
|-------------------|------------------------------|-------------------|
| Original Baseline | HCV RNA value: _____ | Date Drawn: _____ |
| Current Baseline | HCV RNA value: _____ | Date Drawn: _____ |
| | <i>(Within past 4 weeks)</i> | |
| Tx Week 4 | HCV RNA value: _____ | Date Drawn: _____ |
| Tx Week Other | HCV RNA value: _____ | Date Drawn: _____ |

If HCV RNA is detectable at week 4 of treatment, repeat quantitative HCV RNA viral load testing is recommended after 2 additional weeks of treatment (treatment week 6). If quantitative HCV viral load has increased by greater than 10-fold (>1 log₁₀ IU/mL) on repeat testing at week 6 (or thereafter), then discontinuation of HCV treatment is recommended.

PREVIOUS HEPATITIS C TREATMENTS

| | | |
|--|--|--|
| <input type="checkbox"/> Treatment Experienced with (check ALL that apply) | <input type="checkbox"/> Treatment naïve | <input type="checkbox"/> Daklinza™ (daclatasvir) |
| <input type="checkbox"/> Epclusa® (sofosbuvir/velpatasvir) | <input type="checkbox"/> Harvoni® (ledipasvir-sofosbuvir) | <input type="checkbox"/> Incivek® (telaprevir) |
| <input type="checkbox"/> Interferon | <input type="checkbox"/> Olysio™ (simeprevir) | <input type="checkbox"/> Peginterferon |
| <input type="checkbox"/> ribavirin | <input type="checkbox"/> Sovaldi® (sofosbuvir) | <input type="checkbox"/> Technivie® (ombitasvir/paritaprevir/ritonavir) |
| <input type="checkbox"/> Zepatier™ (elbasvir and grazoprevir) | <input type="checkbox"/> Viekira Pak™ (ombitasvir/paritaprevir/ritonavir) with dasabuvir | <input type="checkbox"/> Viekira XR (ombitasvir/paritaprevir/ritonavir; dasabuvir) |

Document dates received: _____

Use of samples to initiate therapy **does not meet step-edit/preauthorization criteria.**

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

Patient Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

REVISED/UPDATED: 6/25/2017 8/30/2017

Optima Health Community Care

Hepatitis C Therapy Patient Treatment Agreement

Prescriber Instructions: Please submit the completed agreement with the **initial prior authorization requests.**

Patient Instructions: By reading and signing this agreement, I acknowledge that I have been informed about the requirements of the treatment program and understand what is expected of me. I can refuse to sign this agreement, but treatment will not be started until and unless I sign this agreement.

| | |
|---|--|
| Patient Information | Prescriber Information |
| Name: _____ _____ | Name: _____ _____ |
| Optima Health Member ID Number: _____ | Optima Provider ID Number or NPI: _____ |
| Date of Birth: _____ | Office Contact Name: _____ |
| Hepatitis C Medication Regimen: _____ _____ | Telephone Number: _____ Fax Number: _____ |
| 1. I have been told how to take my hepatitis-C medicines. I understand how to take them. I am aware of possible side effects. I understand why it is important to finish all the therapy. | |
| 2. I will take my hepatitis-C medicines like my doctor said. I understand that missing doses of medicine may cause the treatment to fail. | |
| 3. I understand that if I miss more than 3 doses in one month, Medicaid may no longer pay for my hepatitis-C medicines. | |
| 4. I will tell my doctor and pharmacist the medicines I take. I understand there may be some medicines I cannot take with my hepatitis-C medicines. | |
| 5. I understand that Medicaid may only pay for hepatitis-C medicines for a certain number weeks over my lifetime. | |
| 6. I understand that past use of certain hepatitis-C medicines may keep me from using medicines like them again. | |
| 7. I am not currently using IV drugs or abusing alcohol. | |
| 8. I will not use IV drugs or abuse alcohol (which could seriously damage my liver) while on treatment or after completion of treatment. | |
| 9. I am (OR my female partner is) not pregnant. | |
| 10. I am (OR my female partner is) not planning on getting pregnant while I am on my hepatitis-C medicines and for at least 6 months after I finish them. | |
| 11. I (OR my female partner) will use two forms of non-hormonal birth control while I am taking my hepatitis-C medicines and for at least 6 months after I finish taking them. | |
| 12. I (OR my female partner) will have monthly pregnancy testing while I am taking my hepatitis-C medicines. | |

I have read the above statements and understand the agreement.

Patient Signature: _____ **Date:** _____

Physician Signature: _____ **Date:** _____